BMO Capital Initiates Coverage On Nuvalent with Outperform Rating, Announces Price Target of $28
BMO Capital analyst Etzer Darout initiates coverage on Nuvalent (NASDAQ:NUVL) with a Outperform rating and announces Price Target of $28.
Nuvalent Announces Clinical Progress On Parallel Lead Programs NVL-520 And NVL-655 For NSCLC And Solid Tumor Cancers
Preliminary dose-escalation data anticipated in second half of 2022 for ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive NSCLC and other solid tumors
First patient dosed in
Nuvalent Q1 EPS $(0.36) Up From $(2.20) YoY
Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(0.36) per share. This is a 83.64 percent increase over losses of $(2.20) per share from the same period last year.
Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity With ROS1-Selective Inhibitor NVL-520 And ALK-Selective Inhibitor NVL-655 At AACR Annual Meeting 2022
Nuvalent, Inc., (NASDAQ:NUVL) a clinical-stage biopharmaceutical company creating precisely targeted therapies for patients with cancer, today announced new data to support broad clinical exploration of its
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.